‹ ›
MYP_062242
← PREVIOUS NEXT → BACK
Basic Information
ENF (T-20)
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Anti-Pneumovirus ▸ Anti-RSV
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
36 amino acids
C202H298N50O64
Standard
Sequence
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
Physicochemical Analysis
4450.82 Da
4.30
-5.14
-5.41
-0.1427
-0.88
0.46
-0.05
62.65
89.44
0.1389
17990.00
17990.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1894.02
-14.96
63.0
60.0
150.0
316.0
9.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0394032 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
Qualitative inhibition
PaperHighly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors PatentUS7919101
RECORD: Rec_0409390 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV gp41 HR2 fusion inhibitor
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibitor
HIV, Simian immunodeficiency virus
PaperMode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage; Patent: Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity PMID11027678 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/11027678/ PatentUS 7575750 B2
RECORD: Rec_0410233 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV-2 (ROD,ST) | TZM-bl cells
0.26368-0.82901 μM
IC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0422701 VERIFIED: YES
Provenance & Taxonomy
Human immunodeficiency virus 1 [Virus]; synthetic construct [Synthetic]
HIV fusion inhibitor
11676;32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibitor
HIV-1 gp41
Clinical/Human: 3.8 ± 0.6 h
PaperPharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide PMID15656696 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15656696/
FIRST PREV 1 ... 12 13 14
Showing 4 records on this page · Page 14 of 14